High-Tech Gründerfonds

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 39
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 34
Rounds per year 2.44
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.06
Exits 1
Key employees 8
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Software
  • Information Technology
  • Biotechnology
  • SaaS
  • Health Care
Summary

The overall number of key employees were 16.

The typical startup value when the investment from High-Tech Gru00fcnderfonds is 5-10 millions dollars. The increased amount of exits for fund were in 2019. The important activity for fund was in 2013. The fund is constantly included in 25-48 investment rounds annually. The common things for fund are deals in the range of 1 - 5 millions dollars.

The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Mobile, Health Care. Among the various public portfolio startups of the fund, we may underline Outfittery, Mister Spex, GWA Hygiene

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the High-Tech Gru00fcnderfonds, startups are often financed by KfW, Peppermint Venture Partners, Earlybird Venture Capital. The meaningful sponsors for the fund in investment in the same round are Neuhaus Partners, NRW.BANK, MBG Baden Wuerttemberg. In the next rounds fund is usually obtained by Wellington Partners, Creathor Ventures, bm-t beteiligungsmanagement thu00fcringen.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Blickfeld

Electronics
Manufacturing
Sensor
Software
$31M08 Dec 2021 Munich, Bavaria, Germany

Emergence Therapeutics

Fitness
Health Care
Wellness
$102M07 Dec 2021 Duisburg, Nordrhein-Westfalen, Germany

Kiutra

Electronics
24 Nov 2021 Germany, Bavaria, Germany

Innerspace

23 Nov 2021 Austria, Tyrol, Austria

Nebula Biocides

$1M10 Nov 2021 Greifswald, Mecklenburg-Vorpommern, Germany

anybill

Apps
FinTech
Information Technology
Retail
Retail Technology
Software
$1M27 Oct 2021 Regensburg, Bayern, Germany

Computomics GmbH

Biotechnology
14 Oct 2021 Germany, Baden-Württemberg, Germany

FlyNex

Drones
SaaS
Software
$5M08 Oct 2021 Leipzig, Saxony, Germany

FinMarie

Finance
Financial Services
Wealth Management
$1M07 Oct 2021 Berlin, Berlin, Germany
News
Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

Alentis Therapeutics Raises $67M in Series B Financing

– Alentis Therapeutics from Basel develops new treatments for fibrotic diseases.
– The company raised $67m in Series B financing round.
– The round was led by Morningside Venture Investments, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital.
– The new investment will be used to support the company’s drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent High-Tech Gründerfonds?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: